



## CYFARFOD BWRDD PRIFYSGOL IECHYD UNIVERSITY HEALTH BOARD MEETING

<b>DYDDIAD Y CYFARFOD: DATE OF MEETING:</b>	25 November 2021
<b>TEITL YR ADRODDIAD: TITLE OF REPORT:</b>	Haematology and Coagulation Managed Service Contract Award
<b>CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:</b>	Andrew Carruthers, Director of Operations
<b>SWYDDOG ADRODD: REPORTING OFFICER:</b>	Dylan Jones, Blood Science Service Lead

**Pwrpas yr Adroddiad (dewiswch fel yn addas)**

**Purpose of the Report (select as appropriate)**

Ar Gyfer Penderfyniad/For Decision

### ADRODDIAD SCAA

#### SBAR REPORT

##### Sefyllfa / Situation

The purpose of this paper is to present a recommendation for consideration and approval to award the Managed Service agreement of Haematology and Coagulation equipment, reagent, and consumables. Further approval will be required at Welsh Government level, due to the total contract value being greater than the £1,000,000 threshold.

The recommendation is based on the results of the evaluation carried out by the representatives appointed by the Contracting Authority to form the Procurement Evaluation Panel.

This Commercial in Confidence Procurement Outcomes Report has not been attached, as it contains sensitive information and must not be disclosed or discussed with any third party; however, more detailed information is available within the main body of the document which has been shared with Board Members as part of In-Committee Board papers.

##### Cefndir / Background

Pathology has implemented an integrated Blood Sciences strategy delivered as a network across the four laboratory sites within the Acute Hospitals. This managed service contract procurement is a central requirement to support this strategy and it is essential that the equipment and service requirements are to be specified to meet service delivery needs. The procurement tender will require the successful supplier to provide a managed service that will deliver the quantity and range of Haematology and Coagulation testing required by the Health Board.

The geography and demographics of the Health Board, along with the current configuration of acute services, dictate that 24/7 cover for Blood Science will continue on all 4 sites.

Pathology has successfully delivered a Managed Service Solution for both Clinical Biochemistry and Blood Transfusion, achieving Health Board wide integrated solutions, providing increased standardisation of services, improved efficiency and benefits in terms of economies of scale.

The aim of the tender is to standardise Haematology and Coagulation provision to meet clinical requirement across the network, within a cost benefit framework. An integrated equipment and IT solution across the four sites will be required, allowing free flow of work within and between departments where needed. The solution will require analytical automated equipment to be available on all sites, appropriate for workload. The solution will need to comply with UKAS standards and demonstrate appropriate assay performance to ensure accurate and precise results. Pathology wish to ensure the solution is innovative and permits the evolution of technology to allow optimisation of service and cost benefit achievement.

### **Asesiad / Assessment**

The procurement process was managed by NHS Shared Business Services (NHS SBS) on behalf of the Hywel Dda UHB (HDdUHB), using their electronic procurement system (EU-Supply) to administrate all communications with bidders and receipt of completed tenders.

The procurement process started with a market engagement exercise, using the NHS SBS Clinical Managed Services Framework SBS/18/OA/FBY/9308 and inviting interest from all eligible framework suppliers to opt in/opt out of the procurement process. This was also used to gather feedback on the scope of requirements and further information with regards to the suppliers' capability. Following further development of the equipment specifications, refinement of the scope of requirements and engagement with HDdUHB, the mini-competition Invitation to Quote (ITQ) documents were developed and released to these suppliers on 4<sup>th</sup> June 2021.

The ITQ advertisement received 3 responses. The financial model template and bid response questionnaire were evaluated in accordance with the evaluation process. The evaluation involved a review of all bids received by individual evaluation panel members, subsequently meeting together to agree a consensus evaluation grading for each element of the bid on behalf of the Contracting Authority.

Final moderated scores of the Evaluation Panel resulted in weighted scoring being applied in accordance with the weightings published to bidders at the commencement of the procurement. The successful bidder was the managed service contract supplier who achieved the highest overall score.

### **Argymhelliad / Recommendation**

The Board is requested to approve the Procurement Evaluation Panel recommendation in respect of the successful bidder noted within the Haematology Procurement Outcomes Report, prior to gaining further approval from Welsh Government.

<b>Amcanion: (rhaid cwblhau)</b> <b>Objectives: (must be completed)</b>	
Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	N/A
Safon(au) Gofal ac Iechyd: Health and Care Standard(s):	2.9 Medical Devices, Equipment and Diagnostic Systems 3.3 Quality Improvement, Research and Innovation
Amcanion Strategol y BIP: UHB Strategic Objectives:	3. Striving to deliver and develop excellent services
Amcanion Llesiant BIP: UHB Well-being Objectives: <a href="#">Hyperlink to HDdUHB Well-being Objectives Annual Report 2018-2019</a>	10. Not Applicable

<b>Gwybodaeth Ychwanegol:</b> <b>Further Information:</b>	
Ar sail tystiolaeth: Evidence Base:	Procurement process was managed by NHS Shared Business Services (NHS SBS) on behalf of the Hywel Dda
Rhestr Termau: Glossary of Terms:	Referenced within the paper
Partïon / Pwyllgorau â ymgynhorwyd ymlaen llaw y Cyfarfod Bwrdd Iechyd Prifysgol: Parties / Committees consulted prior to University Health Board:	NHS Shared Business Services (NHS SBS)

<b>Effaith: (rhaid cwblhau)</b> <b>Impact: (must be completed)</b>	
Ariannol / Gwerth am Arian: Financial / Service:	Referenced within the paper
Ansawdd / Gofal Claf: Quality / Patient Care:	Adverse quality and/or patient care outcomes/impacts
Gweithlu: Workforce:	N/A
Risg: Risk:	N/A
Cyfreithiol: Legal:	NHS SBS Clinical Managed Services Framework SBS/18/OA/FBY/9308 procurement process followed
Enw Da: Reputational:	None, due to above procurement process being followed

<b>Gyfrinachedd: Privacy:</b>	N/A
<b>Cydraddoldeb: Equality:</b>	N/A